Publication | Open Access
Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus–A randomized, placebo-controlled cross-over study
17
Citations
24
References
2022
Year
Despite effect on weight-loss, Hba1c and biomarkers, treatment with empagliflozin for 12 weeks did not improve CFVR in patients with DM2.
| Year | Citations | |
|---|---|---|
Page 1
Page 1